These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22645158)

  • 1. Heart rate variability parameters of myxomatous mitral valve disease in dogs with and without heart failure obtained using 24-hour Holter electrocardiography.
    Oliveira MS; Muzzi RA; Araújo RB; Muzzi LA; Ferreira DF; Nogueira R; Silva EF
    Vet Rec; 2012 Jun; 170(24):622. PubMed ID: 22645158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
    Rasmussen CE; Falk T; Zois NE; Moesgaard SG; Häggström J; Pedersen HD; Ablad B; Nilsen HY; Olsen LH
    J Vet Intern Med; 2012; 26(1):76-84. PubMed ID: 22151356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Holter monitoring of small breed dogs with advanced myxomatous mitral valve disease with and without a history of syncope.
    Rasmussen CE; Falk T; Domanjko Petrič A; Schaldemose M; Zois NE; Moesgaard SG; Ablad B; Nilsen HY; Ljungvall I; Höglund K; Häggström J; Pedersen HD; Bland JM; Olsen LH
    J Vet Intern Med; 2014; 28(2):363-70. PubMed ID: 24417236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Holter monitoring in 36 dogs with myxomatous mitral valve disease.
    Crosara S; Borgarelli M; Perego M; Häggström J; La Rosa G; Tarducci A; Santilli RA
    Aust Vet J; 2010 Oct; 88(10):386-92. PubMed ID: 20854294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of heart rate turbulence in dogs with myxomatous mitral valve disease.
    Dos Santos JP; Lucina SB; da Costa BN; Olaguivel KLC; Tuleski GLR; Sousa MG
    Open Vet J; 2021; 11(4):635-644. PubMed ID: 35070858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study.
    Boswood A; Gordon SG; Häggström J; Vanselow M; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
    J Vet Intern Med; 2020 May; 34(3):1108-1118. PubMed ID: 32200574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.
    Li Q; Heaney A; Langenfeld-McCoy N; Boler BV; Laflamme DP
    BMC Vet Res; 2019 Nov; 15(1):425. PubMed ID: 31775756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration.
    Pirintr P; Saengklub N; Limprasutr V; Sawangkoon S; Kijtawornrat A
    J Vet Med Sci; 2017 Sep; 79(9):1480-1488. PubMed ID: 28717064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Poincaré plot derived from 5-min electrocardiography in dogs with myxomatous mitral valve disease.
    Baisan RA; Turcu CA; Condurachi EI; Vulpe V
    Vet Q; 2023 Dec; 43(1):1-10. PubMed ID: 37165892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation.
    Morgan KRS; Monteith G; Raheb S; Colpitts M; Fonfara S
    Vet J; 2020 Sep; 263():105518. PubMed ID: 32928487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
    Nakamura K; Kawamoto S; Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M
    J Vet Intern Med; 2017 Mar; 31(2):316-325. PubMed ID: 28145607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs.
    Pirintr P; Saengklub N; Boonpala P; Hamlin RL; Kijtawornrat A
    BMC Vet Res; 2023 Oct; 19(1):201. PubMed ID: 37821927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QT instability, an indicator of augmented arrhythmogenesis, increases with the progression of myxomatous mitral valve disease in dogs.
    Brüler BC; Jojima FS; Dittrich G; Giannico AT; Sousa MG
    J Vet Cardiol; 2018 Aug; 20(4):254-266. PubMed ID: 30031743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron parameters analysis in dogs with myxomatous mitral valve disease.
    Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
    BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease.
    Reimann MJ; Ljungvall I; Hillström A; Møller JE; Hagman R; Falk T; Höglund K; Häggström J; Olsen LH
    Vet J; 2016 Mar; 209():113-8. PubMed ID: 26831162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left atrial deformation and phasic function determined by two-dimensional speckle-tracking echocardiography in dogs with myxomatous mitral valve disease.
    Caivano D; Rishniw M; Birettoni F; Patata V; Giorgi ME; Porciello F
    J Vet Cardiol; 2018 Apr; 20(2):102-114. PubMed ID: 29459124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma and serum serotonin concentrations and surface-bound platelet serotonin expression in Cavalier King Charles Spaniels with myxomatous mitral valve disease.
    Cremer SE; Kristensen AT; Reimann MJ; Eriksen NB; Petersen SF; Marschner CB; Tarnow I; Oyama MA; Olsen LH
    Am J Vet Res; 2015 Jun; 76(6):520-31. PubMed ID: 26000599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.